JP2012520085A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520085A5
JP2012520085A5 JP2011554275A JP2011554275A JP2012520085A5 JP 2012520085 A5 JP2012520085 A5 JP 2012520085A5 JP 2011554275 A JP2011554275 A JP 2011554275A JP 2011554275 A JP2011554275 A JP 2011554275A JP 2012520085 A5 JP2012520085 A5 JP 2012520085A5
Authority
JP
Japan
Prior art keywords
sequence
polynucleotide
expression vector
cell
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011554275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/027365 external-priority patent/WO2010105277A1/en
Publication of JP2012520085A publication Critical patent/JP2012520085A/ja
Publication of JP2012520085A5 publication Critical patent/JP2012520085A5/ja
Pending legal-status Critical Current

Links

JP2011554275A 2009-03-13 2010-03-15 生物活性rnaの送達のための組成物及び方法 Pending JP2012520085A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16028809P 2009-03-13 2009-03-13
US16028709P 2009-03-13 2009-03-13
US61/160,287 2009-03-13
US61/160,288 2009-03-13
PCT/US2010/027365 WO2010105277A1 (en) 2009-03-13 2010-03-15 Compositions and methods for the delivery of biologically active rnas

Publications (2)

Publication Number Publication Date
JP2012520085A JP2012520085A (ja) 2012-09-06
JP2012520085A5 true JP2012520085A5 (enExample) 2013-02-21

Family

ID=42728852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011554275A Pending JP2012520085A (ja) 2009-03-13 2010-03-15 生物活性rnaの送達のための組成物及び方法

Country Status (8)

Country Link
US (2) US8569065B2 (enExample)
EP (1) EP2406379A4 (enExample)
JP (1) JP2012520085A (enExample)
KR (1) KR20110128345A (enExample)
CN (1) CN102625842A (enExample)
AU (1) AU2010223888A1 (enExample)
CA (1) CA2755245A1 (enExample)
WO (1) WO2010105277A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
US20130101512A1 (en) * 2010-03-12 2013-04-25 Chad A. Mirkin Crosslinked polynucleotide structure
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9880151B2 (en) * 2011-05-23 2018-01-30 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013096958A1 (en) * 2011-12-23 2013-06-27 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
WO2013101690A1 (en) * 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
KR20160021076A (ko) * 2013-03-15 2016-02-24 테출론 인코포레이티드 스타필로코커스 아우레우스 감염의 치료를 위한 안티센스 분자
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
JP6588024B2 (ja) 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性hsvベクター
JP6744224B2 (ja) 2014-02-14 2020-08-19 シンヴィヴォ コーポレイション 核酸ベクターおよびその使用
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3183007B1 (en) 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
JP6741673B2 (ja) 2014-10-06 2020-08-19 イグジキュア, インコーポレーテッドExicure, Inc. 抗tnf化合物
US9816080B2 (en) * 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
EP4089166A1 (en) 2016-01-27 2022-11-16 Oncorus, Inc. Oncolytic viral vectors and uses thereof
US11639371B2 (en) * 2016-02-17 2023-05-02 The Chinese University Of Hong Kong Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases
CN109414414A (zh) 2016-03-16 2019-03-01 戴维·格拉德斯通研究所 用于治疗肥胖症和/或糖尿病以及用于鉴定候选治疗剂的方法和组合物
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
KR20200042904A (ko) 2017-07-26 2020-04-24 온코루스, 인크. 종양용해성 바이러스 벡터 및 그의 용도
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
EP3818167A4 (en) * 2018-07-05 2022-04-13 The Regents of The University of California COMPOSITIONS AND METHODS FOR DELIVERING RNA TO A CELL
US20250263690A1 (en) * 2022-06-15 2025-08-21 Duke University Protein library display systems and methods thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
JP2002533128A (ja) * 1998-12-31 2002-10-08 アドバンスド リサーチ アンド テクノロジー インスティテュート アデノ随伴ウイルス2による感染のためのコレセプターとしてのヒト線維芽細胞増殖因子レセプター1
WO2002027031A2 (en) * 2000-09-28 2002-04-04 Cellomics, Inc. Methods and reagents for live-cell gene expression quantification
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
US20040005593A1 (en) * 2002-03-06 2004-01-08 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of siRNA molecules
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
AU2003279004B2 (en) * 2002-09-28 2009-10-08 Massachusetts Institute Of Technology Influenza therapeutic
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
CN101415816A (zh) * 2006-02-02 2009-04-22 雷格内泰克公司 表征生物活性化合物的方法
CA2638915A1 (en) * 2006-02-10 2007-08-23 The Regents Of The University Of California Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CN100549179C (zh) * 2006-08-07 2009-10-14 汪运山 胃癌靶向AFP基因的siRNAs表达载体及其用途
JP2010517587A (ja) * 2007-02-15 2010-05-27 ディーエスエム アイピー アセッツ ビー.ブイ. 関心のある化合物を生産するための組み換え宿主細胞
ES2562817T3 (es) * 2010-02-24 2016-03-08 Arrowhead Research Corporation Composiciones para el suministro dirigido de ARNip

Similar Documents

Publication Publication Date Title
JP2012520085A5 (enExample)
JP2022046503A5 (enExample)
WO2012172277A4 (en) Simian adenovirus and hybrid adenoviral vectors
CN102558309B (zh) 一对转录激活子样效应因子核酸酶及其编码基因与应用
JP2019524140A5 (enExample)
JP2018532705A5 (enExample)
JP2018528237A5 (enExample)
HRP20230150T1 (hr) Konstrukcija kimernog antigenskog receptora koji cilja cd20 antigen i identifikacija aktivnosti njegovih inženjerskih t-stanica
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
EP2852407A1 (fr) Cassettes d'expression procaryotes régulées par le stress.
JP2013521789A5 (enExample)
JP2011062217A5 (enExample)
WO2008084115A3 (en) Lactococcus promoters and uses thereof
JP2018515096A5 (enExample)
JP2013530689A5 (enExample)
JP2010539926A5 (enExample)
JP2009528843A5 (enExample)
JP2014523238A5 (enExample)
JP2020523983A5 (enExample)
JP2011520424A5 (enExample)
JP2016503434A5 (enExample)
JP2011505850A5 (enExample)
CN116218904B (zh) 一种可提高工程化细胞外泌体中特定核酸分子载量的方法及其应用
WO2013052814A3 (en) E1 enzyme mutants and uses thereof
CN109929865A (zh) 基于gal4-uas系统的crispr辅助反式增强子激活基因表达的方法及其应用